Drug Profile
Ivosidenib - Servier
Alternative Names: Tuoshuvo; AG-120; CS 3010; ivonib tablet; S-95031; TIBSOVO; Tosuvo; TuoshuwoLatest Information Update: 23 Feb 2024
Price :
$50
*
At a glance
- Originator Agios Pharmaceuticals
- Developer Agios Pharmaceuticals; Bristol-Myers Squibb; CStone Pharmaceuticals; HOVON Foundation; Servier; University of Pittsburgh Medical Center
- Class Antineoplastics; Cyclobutanes; Nitriles; Pyridines; Pyrrolidines; Small molecules
- Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acute myeloid leukaemia; Cholangiocarcinoma; Myelodysplastic syndromes
- Phase II Glioma; Solid tumours
Most Recent Events
- 04 Jan 2024 Institut de Recherches Internationales Servier completes a phase I trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in the US and France (NCT02073994)
- 21 Dec 2023 Servier acquires Ivosidenib from CStone Pharmaceuticals in China, Hong Kong, Macau, Taiwan and Singapore
- 21 Dec 2023 Ivosidenib is no longer licensed to CStone Pharmaceuticals in China, Hong Kong, Macau, Taiwan and Singapore